Combination treatment for multiple myeloma that has returned
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has returned or not responded to at least one previous treatment.
- Your cancer shows a measurable sign in blood, urine, or bone marrow (like a certain level of protein or plasma cells).
- You are planning to receive a treatment combination of carfilzomib, daratumumab, and dexamethasone.
- You are generally able to take care of yourself (ECOG performance status 0-2).
- Your blood counts, liver and kidney function are within study limits.
- You have not been resistant to carfilzomib or daratumumab within the last 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests whether a new combination of drugs (daratumumab and teclistamab) works better than the usual treatments for multiple myeloma that has come back or stopped responding, especially in people with a high-risk form of the disease. Participants will be randomly assigned to get either the new combo or one of the standard combos.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
This trial tests a new treatment that combines two types of therapy: CAR T-cell therapy (which uses your own immune cells to fight the cancer) and daratumumab (a drug that targets a protein on myeloma cells). The goal is to see if this combination can help people with relapsed or refractory multiple myeloma.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This Phase 2 trial tests iberdomide plus daratumumab, carfilzomib, and dexamethasone in people whose multiple myeloma has come back or not responded. The goal is to increase how often patients reach “MRD-negative” status, meaning very small amounts of cancer cells are not detectable, which may help improve outcomes.
Hear when a new Recurrent Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.